COMPANY PROFILE

Tyra Biosciences

Tyra Biosciences is a biotechnology company targeting new pathways of acquired resistance in oncology with purpose-built drugs

Carlsbad, United StatesFounded 2018Biotech & Life Sciences

Valuation $1–2.5B Latest valuation · 2026

Headcount 100–500 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Tyra Biosciences

Tyra Biosciences is a clinical-stage biotechnology company that develops next-generation precision medicines for oncology and genetically defined diseases. The company's proprietary SNAP platform enables the rapid and precise development of therapies that target specific genetic mutations, aiming to overcome drug resistance and improve treatment outcomes. Tyra's pipeline includes TYRA-300, an FGFR3-selective inhibitor for the treatment of achondroplasia and non-muscle invasive bladder cancer, and TYRA-200, an FGFR1/2/3 inhibitor with a focus on intrahepatic cholangiocarcinoma and other solid tumors.

Read full description

The company's business model revolves around the research, development, and eventual commercialization of its drug candidates. Tyra Biosciences collaborates with academic institutions and other partners to advance its research and clinical trials. The company generates revenue through venture capital funding and public offerings, with future revenue streams expected from drug sales and licensing agreements upon regulatory approval.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2018
Headquarters: Carlsbad, United States
Employees: 100
Open positions: 31
Dealroom signal: 93.1/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Precision Medicine, Verified Unicorns and $1B Exits, Post IPO $1B, Biotech and Pharma, DT and LS, science-based
Technology: Deep Tech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Latest news

Press, funding announcements and product moves mentioning Tyra Biosciences.

See all news

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
PRIVATE PLACEMENT VCOther financing	Feb 2024	$200M	—	5AM Ventures · RA Capital Management · OrbiMed · BVF Partners	↗
IPOOther financing	Sep 2021	$199M	$626M	Undisclosed	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Growth	Margin
2026	—	—
2025	—	—
2024	—	—
2023	—	—
2022	—	—
2021	—	—
2020	—	—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Tyra Biosciences website traffic

Latest recorded traffic for Tyra Biosciences is 10K monthly website visits, up 0% over the last three months. Tyra Biosciences's team grew 26.6% over the past year.

Latest monthly visits10K 3-month web change0% 1-year team growth+26.6%

Monthly website visitsDec 2018–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Director/Associate Director Biostatistics2333 State St, Carlsbad, CA 92008, USA · Other · Sep 4, 2026 Senior Director, Global Pharmacovigilance (PV) Operations & Systems2333 State St, Carlsbad, CA 92008, USA · Human Resources · Aug 25, 2026 Senior Clinical Trial Manager2333 State St, Carlsbad, CA 92008, USA · Other · Aug 18, 2026 Executive Director, Clinical Development UTUCCarlsbad, CA · Other · Aug 18, 2026 Manager – Accounting and SEC ReportingCarlsbad, CA · Accounting · Aug 6, 2026 Associate Director Regulatory Affairs Strategy2333 State St, Carlsbad, CA 92008, USA · Full-Stack Development · Jul 21, 2026 Director, Medical Writing2333 State St, Carlsbad, CA 92008, USA · Other · Jul 16, 2026 Senior Clinical Trial Manager (Pharmacology Operations)2333 State St, Carlsbad, CA 92008, USA · Other · Jul 2, 2026

8 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
DTDyne TherapeuticsDyne Therapeutics is a new biotechnology company pioneering targeted therapies for patients with serious muscle diseases	Waltham, United States	Operational	316	$165M	$4B
NUNuvalentTargeted small-molecule cancer therapies for kinase-driven cancers	Cambridge, United States	Acquired
ETEdgewise TherapeuticsA new biotech company harnessing proven expertise and understanding of skeletal muscle	Boulder, United States	Acquired
PMPraxis Precision MedicinesDeveloping therapies for central nervous system disorders based on genetic insights into neuronal imbalance	Cambridge, United States	Operational
CECelcuityPrecision oncology therapies guided by companion diagnostics	Minneapolis, United States	Operational
TTTP TherapeuticsClinical-stage structure-based drug design company for the discovery and development of precision medicines for cancer and other diseases	San Diego, United States	Acquired
ARArQuleSmall molecules for precision medicine	Woburn, United States	Acquired
RTRapport TherapeuticsDeveloping recision medicines to match the complexity of the human brain	Boston, United States	Operational